Bg pattern

LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Liraglutida Zentiva 6 mg/ml solution for injection in pre-filled pen

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Liraglutida Zentiva and what is it used for
  2. What you need to know before you use Liraglutida Zentiva
  3. How to use Liraglutida Zentiva
  4. Possible side effects
  5. Storage of Liraglutida Zentiva
  6. Contents of the pack and other information

1. What is Liraglutida Zentiva and what is it used for

Liraglutida Zentiva contains the active substance liraglutide. It helps your body to lower your blood sugar level only when your blood sugar level is too high. It also slows down the movement of food from your stomach.

Liraglutide is used on its own if your blood sugar level is not controlled with diet and exercise alone, and you cannot use metformin (another diabetes medicine).

Liraglutide is used together with other diabetes medicines, when these are not enough to control your blood sugar level. These may be:

  • oral anti-diabetics (such as metformin, pioglitazone, sulfonylurea, sodium-glucose cotransporter 2 (SGLT2) inhibitor) and/or insulin.
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Liraglutida Zentiva

Do not use Liraglutida Zentiva

  • if you are allergic to liraglutide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse:

  • before you start using liraglutide.
  • if you have or have had pancreatitis.

If you know you are going to have surgery, tell your doctor that you are taking this medicine.

This medicine should not be used if you have type 1 diabetes (your body does not produce any insulin) or diabetic ketoacidosis (a complication of diabetes characterized by high blood sugar and increased breathing rate). It is not an insulin and should not be used as a substitute for insulin.

The use of liraglutide is not recommended if you are on dialysis.

The use of liraglutide is not recommended if you have severe liver disease.

The use of liraglutide is not recommended if you have severe heart failure.

This medicine should not be used if you have a severe stomach or gut problem that causes a delay in emptying of the stomach (called gastroparesis), or inflammatory bowel disease.

If you get symptoms of acute pancreatitis, such as severe and persistent stomach pain, you should contact your doctor immediately (see section 4).

If you have thyroid disease, including thyroid nodules and increased size of the thyroid gland, talk to your doctor.

In some cases, when starting treatment with liraglutide, you may experience dehydration (loss of fluids), for example, if you have vomiting, nausea, and diarrhea. It is important to avoid dehydration by drinking plenty of fluids. Contact your doctor if you have any doubts.

Children and adolescents

Liraglutide can be used in adolescents and children from 10 years of age. There is no data available in children under 10 years of age.

Other medicines and Liraglutida Zentiva

Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.

In particular, tell your doctor, pharmacist, or nurse if you are using medicines that contain any of the following active substances:

  • Sulfonylurea (such as glimepiride or glibenclamide) or insulin. You may get low blood sugar (hypoglycemia) when using liraglutide with a sulfonylurea or insulin, as sulfonylureas and insulin increase the risk of hypoglycemia. When you start using these medicines together for the first time, your doctor may tell you to reduce the dose of sulfonylurea or insulin. To see the warning signs of low blood sugar, see section 4. If you are also taking a sulfonylurea (such as glimepiride or glibenclamide) or insulin, your doctor may ask you to have your blood sugar levels tested. This will help your doctor decide if you need to change the dose of sulfonylurea or insulin.
  • If you are taking insulin, your doctor will tell you how to reduce the dose of insulin and recommend that you check your blood sugar level more often to avoid high blood sugar (hyperglycemia) and diabetic ketoacidosis (a complication of diabetes that occurs when the body cannot break down glucose because there is not enough insulin).
  • Warfarin or other anticoagulant medicines. You may need to have more frequent blood tests to check how well your blood is clotting.

Pregnancy and breastfeeding

Tell your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. This medicine should not be used during pregnancy because it is not known if it could harm the baby.

It is not known if liraglutide passes into breast milk, so do not use this medicine during breast-feeding.

Driving and using machines

Low blood sugar (hypoglycemia) may reduce your ability to concentrate. Avoid driving or using machines if you experience symptoms of hypoglycemia. See section 4 for the warning signs of low blood sugar. Talk to your doctor for more information.

Liraglutida Zentiva contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially “sodium-free”.

3. How to use Liraglutida Zentiva

Follow the instructions for administration of this medicine exactly as told by your doctor. If you are not sure, talk to your doctor, pharmacist, or nurse.

  • The starting dose is 0.6 mg once a day for at least one week.
  • Your doctor will tell you when to increase the dose to 1.2 mg once a day.
  • Your doctor may tell you to further increase the dose to 1.8 mg once a day if your blood sugar is not controlled with a dose of 1.2 mg.

Do not change the dose unless your doctor tells you to.

Liraglutide is given as an injection under the skin (subcutaneously). Do not inject into a vein or muscle. The best areas for injection are the front of your thigh, the front of your waist (abdomen), or the top of your arm. Change the injection site every day to reduce the risk of developing lumps under the skin.

The injection can be given at any time of day, with or without food. Once you have decided on the best time of day for you, it is best to inject liraglutide at the same time every day.

Before you use the pen for the first time, your doctor or nurse will show you how to use it.

On the other side of this leaflet, you will find detailed instructions on how to use it.

Injection needles are not included with the pen. For example, you can use disposable needles such as BD Ultra-Fine TM or NovoFine ® as fine as 32 G and up to 8 mm in length.

If you use more Liraglutida Zentiva than you should

If you use more liraglutide than you should, talk to your doctor immediately. You may need medical treatment. You may experience nausea, vomiting, diarrhea, or low blood sugar (hypoglycemia). See the warning signs of low blood sugar in section 4.

In case of overdose or accidental ingestion, talk to your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.

If you forget to use Liraglutida Zentiva

If you forget a dose, use liraglutide as soon as you remember.

However, if more than 12 hours have passed since you should have used liraglutide, skip the missed dose. Give the next dose at the usual time the next day.

Do not use a double dose or increase the dose the next day to make up for the missed dose.

If you stop using Liraglutida Zentiva

Do not stop using this medicine without talking to your doctor. If you stop, your blood sugar levels may increase.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Common: may affect up to 1 in 10 people

  • Low blood sugar (hypoglycemia). The warning signs of low blood sugar may appear suddenly and include: cold sweat, cool pale skin, headache, fast heartbeat, nausea, excessive hunger, visual disturbances, drowsiness, weakness, nervousness, anxiety, confusion, difficulty concentrating, and shakiness. Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. This is more likely to happen if you are also using a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using liraglutide.

Rare: may affect up to 1 in 1,000 people

  • A severe allergic reaction (anaphylactic reaction) with additional symptoms such as breathing problems, swelling of the throat and face, fast heartbeat, etc. If you notice any of these symptoms, seek medical help immediately and talk to your doctor as soon as possible.
  • Intestinal obstruction. A severe form of constipation with additional symptoms such as stomach pain, bloating, vomiting, etc.

Very rare: may affect up to 1 in 10,000 people

  • Cases of pancreatitis (inflammation of the pancreas). Pancreatitis can be a serious and potentially life-threatening disease. Stop using liraglutide and contact your doctor immediately if you notice any of the following serious side effects:

Severe and persistent stomach pain (abdominal pain) that may radiate to the back, as well as nausea and vomiting, as it could be a sign of pancreatitis.

Other side effects

Very common: may affect more than 1 in 10 people

  • Nausea (feeling sick). This side effect usually goes away with time.
  • Diarrhea. This side effect usually goes away with time.

Common

  • Vomiting.

When starting treatment with liraglutide, in some cases, you may experience loss of fluids/dehydration. For example, if you have vomiting, nausea, and diarrhea. It is important to avoid dehydration by drinking plenty of fluids.

  • Headache
  • Indigestion
  • Stomach inflammation (gastritis). The symptoms include stomach pain, nausea, and vomiting.
  • Gastroesophageal reflux disease (GERD). The symptoms include heartburn.
  • Bloated stomach (abdomen) or abdominal pain
  • Abdominal discomfort
  • Constipation
  • Gas (flatulence)
  • Decreased appetite
  • Bronchitis
  • Common cold
  • Dizziness
  • Fast heartbeat
  • Fatigue
  • Toothache
  • Injection site reactions (bruising, pain, irritation, itching, and rash).
  • Increased pancreatic enzymes (such as lipase and amylase).

Uncommon: may affect up to 1 in 100 people

  • Allergic reactions such as itching (pruritus) and hives (urticaria)
  • Dehydration, sometimes with decreased kidney function
  • Malaise (not feeling well)
  • Gallstones
  • Inflamed gallbladder
  • Change in taste
  • Delayed gastric emptying.

Frequency not known: cannot be estimated from the available data

  • Lumps under the skin may occur due to the accumulation of a protein called amyloid (cutaneous amyloidosis; the frequency with which this occurs is not known).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Liraglutida Zentiva

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label of the pen and on the carton after “EXP”. The expiry date is the last day of the month stated.

Before first use:

Store in a refrigerator (2 °C to 8 °C). Do not freeze.

When you start using the pen:

You can store the pen for a month if you keep it below 30 °C or in a refrigerator (2 °C to 8 °C). Do not freeze.

When not in use, keep the pen with the cap on to protect it from light.

Do not use this medicine if you notice that the solution is not clear and colorless or almost colorless.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Contents and Additional Information

Composition of Liraglutida Zentiva

  • The active substance is liraglutide. 1 ml of injectable solution contains 6 mg of liraglutide. A pre-filled pen contains 18 mg of liraglutide.
  • The other components (excipients) are: sodium citrate dihydrate, propylene glycol, phenol, and water for injectable preparations. Additionally, hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.

Appearance and Container Contents of the Product

Liraglutida Zentiva is supplied as a clear and colorless or almost colorless injectable solution in a pre-filled pen. Each pen contains 3 ml of solution, which can deliver 30 doses of 0.6 mg, 15 doses of 1.2 mg, or 10 doses of 1.8 mg.

Liraglutida Zentiva is available in packs of 1, 2, 3, 5, or 10 pens or a multipack containing two packs of 5 pre-filled pens (10 pre-filled pens). Needles are not included.

Only some pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Zentiva, k.s.

U Kabelovny 130

Dolní Mecholupy

102 37 Prague 10

Czech Republic

Manufacturer

Pharmadox Healthcare Limited

KW20A Kordin Industrial Park

Paola PLA 3000

Malta

For further information about this medicinal product, please contact the local representative of the marketing authorization holder:

Zentiva Spain S.L.U.

Avenida de Europa, 19, Edificio 3, Planta 1.

28224 Pozuelo de Alarcón, Madrid

Spain

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Germany: Liraglutid Zentiva 6 mg/ml Injektionslösung in einem Fertigpen

Austria: Liraglutid Zentiva 6 mg/ml Injektionslösung in einem Fertigpen

Denmark, Norway, Sweden: Liraglutid Zentiva

Spain: Liraglutida Zentiva 6 mg/ml solución inyectable en pluma precargada

Estonia, Italy: Liraglutide Zentiva

France: LIRAGLUTIDE ZENTIVA 6 mg/ml solution injectable en stylo prérempli

Lithuania: Liraglutide Zentiva 6 mg/ml injekcinis tirpalas užpildytame švirkštiklyje

Latvia: Liraglutide Zentiva 6 mg/ml šķidrums injekcijām pildspalvveida pilnšļirce

Netherlands: Liraglutide Zentiva 6 mg/ml oplossing voor injectie in een voorgevulde pen

Portugal: Liraglutido Zentiva

Date of the last revision of this leaflet:July 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

INSTRUCTIONS FOR USE OF LIRAGLUTIDA ZENTIVA PRE-FILLED PEN

Read these instructions carefully before using your pen.

Your pen contains 18 mg of liraglutide. You can select doses of 0.6 mg, 1.2 mg, and 1.8 mg.

The pen is designed to be used with disposable needles. Needles are not included.

It is recommended to use disposable BD Ultra-FineTM or NovoFine® needles with this device.

Needle with its parts labeled: outer cap, inner cap, needle, and paper flag rolled around

Liraglutide injectable pen with cap, rubber stopper, cartridge, window, indicator, and dose selector

Preparing the Pen

Check the name and color of the labelon your pen to ensure it contains liraglutide. Using the wrong medicine could cause serious harm.

Remove the cap from the pen.

Pre-filled syringe with numerical scale and blue plunger, hands holding and arrow indicating injection direction

Remove the paper flag from a new disposable needle. Screw the needle straight and firmly onto the pen.

Yellow hand holding a white cylinder with numerical marks and a blue arrow indicating upward movement

Remove the outer cap of the needle and set it aside for later use.

Needle connected to a transparent device with a yellow plunger and white protector, blue arrow indicating connection direction

Remove the inner cap of the needle and discard it.

Yellow hand holding a transparent device with a retracted plunger and visible needle, blue arrow indicating extraction direction

Always use a new needle for each injection. This reduces the risk of contamination, infection, loss of liraglutide, needle blockage, and inaccurate dosing.

Be careful not to bend or damage the needle.

Never attempt to put the inner cap back on the needle. You could stick yourself with the needle.

Maintenance of Your Pen

  • Do not attempt to repair the pen or disassemble it.
  • Keep the pen away from dust, dirt, and all types of liquids.
  • Clean the pen with a damp cloth and a mild detergent.
  • Do not attempt to wash, submerge, or lubricate it; this may damage the pen.

Important Information

  • Do not share your pen or needles with anyone else.
  • Keep your pen out of reach of other people, especially children.
    • Change the injection site each day to reduce the risk of developing lumps under the skin.

Checking the Flow with Each New Pen

Check the flow before the first injection with each new pen. If your pen is already in use, go to "Selecting the Dose", step H.

Turn the dose selector until the indicator points to the flow check symbol.

Hands holding a self-injection device with an arrow indicating compression direction and a flow check symbol

Hold the pen with the needle pointing upwards. Gently tap the cartridge with your finger several times. This will concentrate any air bubbles in the top of the cartridge.

Needle inserted into a transparent device with yellow liquid and a finger pressing the applicator

Hold the needle pointing upwards and press the injection button until the indicator points to 0 mg.

A drop of liraglutide should appear at the tip of the needle. If no drop appears, repeat steps E to G up to four times.

If still no drop of liraglutide appears, change the needle and repeat steps E to G once more.

Do not use the pen if a drop of liraglutide still does not appear. This indicates that the pen is defective, and you should use a new one.

Yellow hand holding a blue auto-injector with a dose indicator and a blue arrow pointing upwards showing preparation

If you have dropped the pen onto a hard surface or suspect that it is not working correctly, always put a new disposable needle on and check the flow before using it.

Selecting the Dose

Always check that the indicator points to 0 mg.

Turn the dose selector until the indicator points to the required dose (0.6 mg, 1.2 mg, or 1.8 mg).

If you accidentally select the wrong dose, to change it, simply turn the dose selector backwards or forwards until the indicator points to the correct dose.

Be careful not to press the injection button while turning the dose selector backwards, as liraglutide may be released.

If the dose selector stops before the indicator points to the required dose, this means that there is not enough liraglutide left for a full dose. In this case, you can:

Divide your dose into two injections:

Turn the dose selector in any direction until the indicator points to 0.6 mg or 1.2 mg. Inject the dose. Then prepare a new pen and inject the remaining number of mg to complete your dose.

You should only divide your dose between the current pen and a new pen if you have received proper training or advice from your healthcare professional. Use a calculator to plan your doses. If you divide your dose incorrectly, you may inject too much or too little liraglutide.

Inject the full dose with a new pen:

If the dose selector stops before the indicator points to 0.6 mg, prepare a new pen and inject the full dose with it.

Medication administration device with a dose indicator showing zero mg and an arrow indicating dose adjustment with hands

Blue dose selector with 0.6 mg highlighted and text indicating “0.6 mg selected”

Blue medical device screen showing a selected dose of 1.2 mg with explanatory text adjacent

White tablet with 1.8 mg highlighted in blue and text indicating “1.8 mg selected”

Do not attempt to select doses other than 0.6 mg, 1.2 mg, or 1.8 mg. The numbers on the window must be exactly aligned with the indicator to ensure you receive the correct dose.

You will hear a click each time you turn the dose selector. Do not use these clicks to select your dose.

Do not use the cartridge scale to measure the amount of liraglutide to be injected, as it is not accurate enough.

Injecting the Dose

Insert the needle under the skin using the injection technique recommended by your doctor or nurse.Then follow these instructions:

Press the injection button until the indicator points to 0 mg. Be careful not to touch the window with your other fingers or press the dose selector from the side while injecting, as this may block the injection. Keep the injection button pressed and keep the needle under the skin for at least 6 seconds. This ensures that the full dose is administered.

Yellow hand pressing an injection device with a dose of 0.6 mg indicated and a window showing 0 mg

Remove the needle.

You may see a drop of liraglutide at the tip of the needle.

This is normal and does not affect your dose.

Needle connected to a transparent device with a yellow plunger and a blue arrow pointing upwards

Insert the needle tip into the outer cap of the needle without touching the needle or the outer cap of the needle.

Transparent device with a needle showing a yellow plunger and a blue arrow indicating push direction

When the needle is protected, carefully press the outer cap of the needle down to the bottom. Then unscrew the needle. Carefully dispose of the needle and replace the pen cap.

When the pen is empty, carefully dispose of it without any needle attached. Please dispose of the pen and needle according to local regulations.

Yellow hand holding an applicator with a white tip and a blue arrow indicating direction over a graduated strip

Always remove the needle after each injection and store your pen without a needle attached.

This reduces the risk of contamination, infection, loss of liraglutide, needle blockage, and inaccurate dosing.

Healthcare providers must be careful when handling used needles to avoid accidental needlestick injuries and infections.

Online doctors for LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN

Discuss questions about LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60
5.0 (29)
Doctor

Dmytro Horobets

Family medicine 7 years exp.

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

  • Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
  • Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
  • Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
  • Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
  • General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
  • Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
  • Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
  • Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.

Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN?
LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN?
The active ingredient in LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN is liraglutide. This information helps identify medicines with the same composition but different brand names.
Who manufactures LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN?
LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN is manufactured by Zentiva K.S.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to LIRAGLUTIDE ZENTIVA 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN?
Other medicines with the same active substance (liraglutide) include BYESILOR 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN, DIAVIC 6 mg/ml INJECTABLE SOLUTION IN PRE-FILLED PEN, PLYZARI 6 mg/mL injectable solution in prefilled pen. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media